Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Apr 30, 2008

166_ip_2008-04-30_f84182c7-0ac5-42d2-b0a7-922eacdfb49d.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Analyst Meeting – Q1/08 Results

April 30, 2008

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Fresenius Group: Successful Start into 2008

S
l
a
e
s		 E
B
I
T		 i
N
t
e
n
c
o
m
e
Q
/
0
8
1		 €
2
9
8
7
m
,		 €
3
7
7
m		 €
1
0
0
m
G
h
t
t
t
t
o
o
n
n
r
w
a
c
s
a
t
c
e
n
c
a
e
s
u
r
r
y
r		 8
%		 7
%		 1
3
%
h
l
G
t
t
t
o
a
a
c
a
r
w
u
t
c
e
n
c
a
e
s
u
r
r
y
r		 %
1		 1
%
-		 8
%

Fresenius Group: Continued Growth in All Business Segments

/
Q
0
8
1		 F
i
r
e
s
e
n
s
u
d
i
l
C
M
e
c
a
a
r
e		 F
i
r
e
s
e
n
s
u
b
i
K
a		 F
i
r
e
s
e
n
s
u
l
i
H
e
o
s		 F
i
r
e
s
e
n
s
u
d
V
a
m
e
l
S
a
e
s
h
G
t
o
r
w		 \$
U
S
2
5
1
2
m
,
8
%		 €
5
4
5
m
3
%
1		 €
0
9
5
m
6
%
1		 €
7
4
m
%
1
E
B
I
T
h
G
t
r
o
w		 \$
S
3
8
9
U
m
7
%		 €
8
7
m
1
3
%		 €
3
8
m
1
9
%		 €
4
m
2
0
%
-

Fresenius Kabi: Update Q1/08

  • Strong start into 2008 8 % organic sales growth
  • Smooth integration of recently acquired companies; financial performance according to expectations
  • Dabur Pharma acquisition strengthens I.V. drug business

Fresenius Helios: Update Q1/08

  • Integration of Krefeld/Hüls hospitals on track
  • Strong acceptance of HELIOS' quality indicators – recommended as a Swiss national quality indicator system
  • At present, moderate privatization activities due to project delays and withdrawals

Fresenius Vamed: Update Q1/08

  • Q1/08 financial performance according to expectations; fully on track for 2008 guidance
  • Excellent increase in order intake (89 %); awarded € 80 m project Tauern Spa World, Kaprun/Austria
  • Order backlog at all-time high (€ 595 m)

Group Financials Q1/08 Outlook 2008

Fresenius Group: Profit and Loss Statement

€
m		 Q
/
1
0
8		 Q
/
1
0
7		 Y
o
l
t
a
c
u
a
t
r
a
e
s		 Y
t
t
c
o
n
s
a
n
t
r
a
e
s		 k
R
e
m
a
r
s
S
l
a
e
s		 2
9
8
7
,		 2
6
7
7
,		 %
1		 8
%		 h
O
i
5
%
t
g
a
n
c
g
o
r
r
w
:
E
B
I
T		 3
7
7		 3
8
0		 1
%
-		 7
%		 M
i
1
3.
5
%
a
r
g
n
:
l
I
t
t
t
n
e
e
s
e
s
r
r
u		 8
4
-		 9
5
-		 1
2
%		 5
%		 i
i
P
t
o
s
v
e
c
u
r
r
e
n
c
y
l
i
t,
m
p
a
c
o
e
a
e
a
g
e
w
r
v
r
t
r
a
e
s
T
a
x
e
s		 1
0
3
-		 1
0
3
-		 0
%		 8
%
-		 T
3
5.
2
%
t
a
x
r
a
e
:
N
i
t
e
n
c
o
m
e		 1
0
0		 9
3		 8
%		 1
3
%

Fresenius Kabi: Organic Sales Growth of 8 %

€
m		 /
Q
0
8
1		 /
Q
0
1
7		 C
h
a
n
g
e		 O
i
r
g
a
n
c
G
h
t
r
o
w
G
e
m
a
n
r
y		 1
0
4		 1
0
6		 2
%
-		 1
%
E
u
r
o
p
e
G
e
e
m
a
n
x
r
y		 2
6
4		 2
3
0		 %
1
5		 6
%
f
A
i
P
i
i
s
a
a
c
c
-		 8
6		 6
9		 2
5
%		 2
8
%
L
i
A
i
t
n
m
e
a
r
c
a		 0
4		 3
0		 3
3
%		 0
%
1
R
W
o		 5
1		 4
8		 6
%		 6
%
T
l
l
t
o
a
s
a
e
s		 5
4
5		 4
8
3		 1
3
%		 8
%

Fresenius Kabi: Excellent EBIT Growth

€
m		 /
Q
1
0
8		 /
Q
1
0
7		 G
h
t
r
o
w
l
T
E
B
I
T
t
o
a
M
i
a
g
n
r		 8
7
1
6
0
%		 7
7
1
5
9
%		 3
%
1
B
R
i
y
e
g
o
n
:
E
o
p
e
u
r
M
i
a
g
n
r		 8
0
2
1.
7
%		 7
2
2
1.
4
%		 1
1
%
l
I
i
t
t
n
e
r
n
a
o
n
a
M
i
a
g
n
r		 2
6
1
4
7
%		 2
2
1
5.
0
%		 1
8
%
C
d
C
&
t
t
R
D
o
p
o
a
e
a
n
o
p
o
a
e
r
r
r
r		 9
1
-		 1
7
-		 2
%
1

Fresenius Helios: Excellent Sales Performance

€
m		 /
Q
1
0
8		 /
Q
1
0
7		 G
h
t
r
o
w
T
l
l
t
o
a
s
a
e
s		 0
9
5		 3
9
4		 6
%
1
b
l
h
d
l
f
l
i
i
i
i
t
t
e
s
a
s
e
c
n
c
p
o
o
o
r
-		 4
6
1		 4
3
9		 *
4
%
(
l
d
)
i
i
i
i
i
1
t
t
<
a
c
q
s
o
n
s
c
o
n
s
o
a
o
n
u
y
r
-		 4
8		 -

* growth rate on a like for like basis

Fresenius Helios: Further Positive Earnings Development

€
m		 /
Q
1
0
8		 /
Q
1
0
7		 G
h
t
r
o
w
l
T
E
B
I
T
t
o
a
M
i
a
r
g
n		 3
8
7
5
%		 3
2
7
3
%		 1
9
%
b
l
h
d
l
f
l
i
i
i
i
t
t
e
s
a
s
e
c
n
c
p
o
r
o
o
-
M
i
a
r
g
n
i
i
t
i
a
c
q
u
s
o
n
s
(
l
da
)
i
t
io
1
co
ns
o
n
<
y
r
-		 2
4
9
1
%
4
-		 3
2
7.
3
%
-

Fresenius Vamed: Excellent Order Intake and Backlog

€
m		 Q
/
1
0
8		 Q
/
1
0
7		 C
h
a
n
g
e
l
l
T
t
o
a
s
a
e
s		 7
4		 7
3		 1
%
B
D
i
i
i
y
v
s
o
n
:
b
P
j
i
t
o
e
c
s
n
e
s
s
r
u		 3
5		 3
7		 5
%
-
S
i
b
i
e
r
v
c
e
u
s
n
e
s
s		 3
9		 3
6		 8
%
*
O
d
i
k
t
r
e
r
n
a
e		 1
2
5		 6
6		 8
9
%
*
O
d
b
k
l
r
e
r
a
c
o
g		 9
5
5		 **
0
5
1		 %
1
7

j
bu
ine
ly
t
p
ro
ec
s
ss
o
n
*
De
3
1,
2
0
0
7
c

Fresenius Vamed: EBIT Development According to Plan

€
m		 /
Q
1
0
8		 /
Q
1
0
7		 C
h
a
n
g
e
T
l
E
B
I
T
t
o
a
i
M
a
r
g
n		 4
%
5
4		 5
6
8
%		 2
0
%
-
N
i
t
e
n
c
o
m
e		 4 4 -

Fresenius Group: Cash Flow

€
m		 /
Q
1
0
8		 /
Q
1
0
7		 Y
Y
o		 R
k
e
m
a
r
s
f
C
h
l
a
s
o
w		 3
0
0		 2
8
4		 6
%		 h
S
i
t
t
o
n
g
e
a
n
n
g
s
g
o
r
r
r
w
h
k
l
C
i
i
i
t
a
n
g
e
n
o
n
g
c
a
p
a
w
r		 2
2
-		 3 --
O
i
C
h
f
l
t
p
e
r
a
n
g
a
s
o
w		 2
7
8		 2
8
7		 %
3
-		 M
i
9
9
%
g
n
a
r
:
C
(
)
t
a
p
e
n
e
x		 6
2
1
-		 3
2
1
-		 2
3
%
-		 h
d
H
i
i
g
c
a
p
e
s
p
e
n
n
g
x
C
h
f
l
a
s
o
w
(
b
f
d
d
d
d
)
i
i
i
i
i
t
e
o
e
a
c
q
s
o
n
s
a
n
e
n
s
r
u
v		 1
1
6		 1
5
5		 2
%
5
-
(
)
A
i
i
i
t
t
c
q
s
o
n
s
n
e
u		 1
5
8
-		 6
3
-		 -
-
d
d
D
i
i
e
n
s
v		 5
-		 4
-		 2
5
%
-
f
C
h
l
F
e
e
a
s
o
r
w
(
f
d
d
d
d
)
i
i
i
i
i
t
t
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 4
7
-		 8
8		 --

Fresenius Business Segments: Financial Outlook 2008 Fully Confirmed

b
F
i
K
i
r
e
s
e
n
u
s
a		 l
h
(
)
S
t
a
e
s
g
r
o
w
c
c
E
B
I
T
i
m
a
r
g
n		 1
2
1
5
%
–
1
6
5
%
~
l
F
i
H
i
e
s
e
n
s
e
o
s
r
u		 l
S
a
e
s
E
B
I
T		 €
2
0
5
0
>
m
,
€
1
6
0
1
0
7
m
–
d
F
i
V
e
e
n
m
e
r
s
u
s
a		 S
l
h
t
e
g
o
a
s
r
w
h
E
B
I
T
t
g
r
o
w		 0
%
5
1
–
0
%
5
1
–
h
F
i
B
i
t
r
e
s
e
n
u
s
o
e
c		 E
B
I
T		 €
5
0
m
~
-

Fresenius Group: Outlook 2008 Fully Confirmed

h
R
t
e
v
e
n
u
e
g
r
o
w
i
t
t
n
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 8
1
0
%
-
h
N
i
t
t
e
n
c
o
m
e
g
r
o
w
i
t
t
n
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 1
0
1
5
%
-
C
a
p
e
x		 €
7
5
0
m
~

Attachments

Fresenius Group:

Overview – Calculation of Minority Interest

€
m		 /
Q
1
0
8		 /
F
Y
0
7
b
f
d
E
i
i
i
i
t
t
t
t
a
n
n
g
s
e
o
e
a
a
n
m
n
o
n
e
e
s
r
r
x
r
y
r		 2
9
3		 1
2
4
1
,
T
a
x
e
s		 1
0
3
-		 4
4
8
-
f
h
M
i
i
i
t
t
t,
t
n
o
n
e
e
s
e
e
o
r
y
r
r		 9
0
-		 3
8
3
-
d
l
b
b
l
F
i
M
i
C
i
i
t
t
t
t
t
e
s
e
n
s
e
c
a
a
e
n
e
n
c
o
m
e
n
o
a
a
e
r
u
r
r
u
(
6
%
)
F
i
4
t
o
r
e
s
e
n
u
s
~		 7
9
-		 3
3
5
-
h
l
d
d
l
M
i
i
i
i
F
i
M
i
C
t
t
t
n
o
r
y
n
e
r
e
s
o
e
r
s
n
r
e
s
e
n
u
s
e
c
a
a
r
e
(
/
2
0
0
S
\$
2
6
Q
/
2
0
0
8
S
\$
6
d
F
Y
7
U
1
U
i
:
m
:
m
a
c
c
o
r
n
g
,
d
l
's
l
)
F
i
M
i
C
F
i
i
S
t
t
t
t
o
e
s
e
n
s
e
c
a
a
e
n
a
n
c
a
a
e
m
e
n
s
r
u
r		 4
-		 1
9
-
h
l
d
b
M
i
i
t
i
t
t
i
F
i
K
i,
n
o
r
y
n
e
r
e
s
o
e
r
s
n
r
e
s
e
n
u
s
a
l
h
d
F
i
H
i
F
i
B
i
t
e
s
e
n
s
e
o
s,
e
s
e
n
s
o
e
c
a
n
r
u
r
u
d
's
l
h
V
A
M
E
D
2
3
%
i
t
t
e
o
e
e
n
a
o
n
e
s
p
u
x
r
w
r		 7
-		 2
9
-
N
i
t
e
n
c
o
m
e		 1
0
0		 4
1
0

Fresenius Group: Debt and Interest Ratios

Fresenius Kabi: Strong Sales Growth in Q1/2008

€
m		 /
Q
0
8
1		 /
Q
0
1
7		 O
i
r
g
a
n
c
G
h
t
r
o
w
S
l
a
e
s		 5
4
5		 4
8
3		 8
%
d
B
P
S
t
t
o
c
e
g
m
e
n
y
r
u
:
f
h
I
i
T
n
o
n
e
p
u
s
r
a
y		 2
8
9		 2
6
2		 %
4
l
l
C
i
i
N
i
i
t
t
n
c
a
o
n
u
r		 2
2
3		 1
9
4		 1
1
%
f
h
l
T
i
T
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y		 3
3		 2
7		 1
9
%

Fresenius Helios: Performance Indicators

/
Q
8
1
0		 /
Q
1
0
7		 C
h
a
n
g
e
f
h
l
(
d
f
d
)
N
i
i
t
t
o
o
o
s
p
a
s
a
e
n
o
p
e
r
o
l
A
t
i
i
c
u
e
c
n
c
s
-
l
P
i
i
t
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 6
0
0
4
2
0		 5
6
3
5
2
1
f
b
d
(
d
f
i
d
)
N
t
o
o
e
s
a
e
n
o
p
e
o
r
l
A
t
i
i
c
u
e
c
n
c
s
-
l
P
i
i
t
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 1
7,
4
4
4
3,
6
8
3
1
3,
7
6
1		 3
1
5,
4
4
1
1,
5
7
5
3,
8
6
8		 3
%
1
8
%
1
3
%
-
d
i
i
*
A
m
s
s
o
n
s
A
(
i
i
)
t
t
t
c
e
c
a
e
n
p
a
e
n
u
r
-		 1
2
7,
1
1
7		 1
0
7,
9
0
9		 1
8
%
*
O
c
c
u
p
a
n
c
y
P
t
t
o
s
a
c
u
e
c
a
r
e
-		 %
7
7		 9
%
7
l
h
f
(
d
)
*
A
t
t
v
e
r
a
g
e
e
n
g
o
s
a
y
a
y
s
(
)
A
D
3
1
t
c
u
e
c
a
r
e
e
c
-
P
(
D
3
1
)
t
t
o
s
a
c
e
c
a
e
e
c
u
r
-		 7.
0
3
1.
6		 7.
1
3
1.
9

*Clinics in Germany

Fresenius Helios:Sales Impact Hospital Acquisitions / Divestitures

Acquisitions Annualized sales

  • Hospital Mariahilf, Hamburg € ~26 m not yet closed
  • Hospital Oberhausen (NRW) € ~20 m consolidated as of Apr 1, 2007
  • Hospital Lengerich (NRW) € ~12 m consolidated as of Apr 1, 2007
  • Municipal hospitals, Krefeld and Hüls € ~175 m consolidated as of Dec 31, 2007

Fresenius Group: Key Figures According to IFRS

€
m		 Q
/
1
0
8
S
G
U
A
A
P		 Q
/
1
0
8
S
I
F
R
S
l
a
e
s		 2
9
8
7
,		 2
8
0
3
,
E
B
I
T		 3
7
7		 3
7
7
l
I
t
t
t
n
e
e
s
e
s
r
r
u		 8
4
-		 8
4
-
i
N
t
e
n
c
o
m
e		 0
0
1		 9
7
f
O
C
h
l
i
t
p
e
n
g
o
r
a
a
s
w		 2
8
7		 8
2
0
l
h
l
B
t
t
t
a
a
n
c
e
s
e
e
o
a		 9
1
5
1
4
,		 1
5
1
6
0
,

Financial Calendar

  • 21.5.2008 Annual General Meeting, Frankfurt/Main
  • 30.7.2008 Report on 1st half 2008
  • 4.11.2008 Report on 1st-3rd quarters 2008

Contact

Birgit Grund SVP Investor Relations Fresenius SE

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.